Dose-finding Phase 1 Trial: Evaluating Safety and Biomarkers Using DK210 (EGFR) for Inoperable Locally Advanced and/or Metastatic EGFR+ Tumors With Progressive Disease Failing Systemic Therapy
NCT #
NCT05704985
Condition(s)
Colorectal Cancer, Head and Neck Cancer, Lung Cancer (NSCLC), Pancreatic Cancer, Renal Cell Cancer, Skin Cancer/ Melanoma, Urothelial Cancer
Molecular Target(s)
EGFR amplification
Drug Classification(s)
Targeted Cytokine Therapy
Agents(s)
DK210 (EGFR)
Phase(s)
I
Mechanism of Action
DK210 is an EGFR-targeting IL2/IL10
Purpose
- How much of the study agent can be given with an acceptable level of side effects
- The effects of the study agent (good and bad)
- How much of the study agent is absorbed into the blood and how fast it is removed
- How the study agent is acting on your body
Location
MCD
Connect With Us
Whether you want to give a spark of hope or you are looking for it, we are here to help. If you have any questions or concerns, please contact us here.